Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hemostemix Inc HMTXF


Primary Symbol: V.HEM

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP... see more

Recent & Breaking News (TSXV:HEM)

Hemostemix Announces Letter of Commitment, Non-Dilutive Funding Structure and $250,000 of Funding by the McGill University Health Centre Foundation

Newsfile January 19, 2023

IIROC Trading Halt - HEM

Canada NewsWire January 19, 2023

Hemostemix Issued 'Your Fountain of Youth' Trademark by Cyprus

Newsfile December 8, 2022

Hemostemix Thanks Neim Malo, Beefstro's Founder, for His ACP-01 Testimonial Interview

Newsfile November 30, 2022

Hemostemix Thanks Six-Time Grammy Award Winner, Howie Lindeman, for his ACP-01 Testimonial Interview

Newsfile November 17, 2022

Hemostemix (TSXV:HEM) advances production automation

Jonathon Brown November 15, 2022

Hemostemix Announces Advancements in Its Automation of Production

Newsfile November 15, 2022

Hemostemix Announces Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Clinical Trials

Newsfile October 26, 2022

Hemostemix Announces Presentation to the Emerging Growth Conference

Newsfile October 25, 2022

Hemostemix (TSXV:HEM) announces NCP-01 study

John Ballem  October 19, 2022

Hemostemix Announces NCP-01 Study to Address a $10 Billion Pain Market

Newsfile October 19, 2022

Hemostemix Announces Exploring Clinical Trial Financing Alternatives

Newsfile October 4, 2022

Hemostemix (TSXV:HEM) appoints Dr. Ernst von Schwarz to its Scientific Advisory Board

John Ballem  September 27, 2022

Hemostemix Announces the Appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to Its Scientific Advisory Board

Newsfile September 27, 2022

Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to Its Scientific Advisory Board

Newsfile September 20, 2022

Hemostemix Announces the Appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board

Newsfile September 16, 2022

Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board

Newsfile September 15, 2022

Hemostemix (TSXV:HEM) appoints Dr. Renzo Cecere to its Scientific Advisory Board

Shoran Devi September 14, 2022

Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board

Newsfile September 14, 2022

Hemostemix Announces Its Presentation to the Emerging Growth Conference

Newsfile September 14, 2022